The only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring in the fasting state, postprandial, or both).
Reveals recent trends toward or away from A1C goals, suggesting improving or worsening control.
Is Independently associated with increased rates of diabetes complications.
When used with A1C, provides a more complete assessment of glycemic control to identify patients that may benefit from closer diabetes management.
Bob and Susan have similar “good” A1Cs, but their glycemic variability is quite different. In fact, up to 40% of patients in moderate to good glycemic control may be experiencing glycemic variability and postprandial glucose spikes. With the addition of the GlycoMark test, recent glycemic control can be more closely assessed and treated. See how GlycoMark can help improve glycemic control.
Simply put, the GlycoMark test is an indicator of glycosuria.
When blood glucose is well-controlled, glucose and 1,5-AG circulate in the bloodstream. The molecules are filtered by the kidneys and reabsorbed by the body. Urinary 1,5-AG is equal to the ingested 1,5-AG.
When glucose exceeds the renal threshold (>180 mg/dL*), glycosuria blocks reabsorption of 1,5-AG. 1,5-AG is excreted in the urine resulting in lower 1,5-AG levels.
The GlycoMark test measures 1,5-AG from a serum or EDTA plasma blood sample.3
Hear from other clinical experts and their use of the GlycoMark test for the detection of glycemic variability and management of glycemic control in patients with diabetes.
*The ADA recommends a postprandial blood glucose goal of 180 mg/dL and an A1C of <7%.1
1Yamanouchi T, et al. Diabetes 1989 Jun; 38(6): 723-729.
2Buse JB, et al. Diabetes Technol Ther. 2003;5(3):355-63.
3GlycoMark Test Product Package Insert, Revision G, 2017.